Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway.

Xu W, Lin H, Zhang Y, Chen X, Hua B, Hou W, Qi X, Pei Y, Zhu X, Zhao Z, Yang L.

J Exp Clin Cancer Res. 2011 Oct 28;30:103. doi: 10.1186/1756-9966-30-103.

2.

Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer.

Cui J, Jiang W, Wang S, Wang L, Xie K.

Curr Pharm Des. 2012;18(17):2464-71. Review.

PMID:
22372504
3.

Targeting Wnt signaling: can we safely eradicate cancer stem cells?

Takahashi-Yanaga F, Kahn M.

Clin Cancer Res. 2010 Jun 15;16(12):3153-62. doi: 10.1158/1078-0432.CCR-09-2943. Epub 2010 Jun 8. Review.

4.

A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.

Prosperi JR, Goss KH.

Curr Drug Targets. 2010 Sep;11(9):1074-88. Review.

PMID:
20545611
5.

Targeting the Wnt/β-catenin signaling pathway in human cancers.

Yao H, Ashihara E, Maekawa T.

Expert Opin Ther Targets. 2011 Jul;15(7):873-87. doi: 10.1517/14728222.2011.577418. Epub 2011 Apr 12. Review.

PMID:
21486121
6.

The Wnt/β-catenin pathway in ovarian cancer: a review.

Arend RC, Londoño-Joshi AI, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2013 Dec;131(3):772-9. doi: 10.1016/j.ygyno.2013.09.034. Epub 2013 Oct 11. Review.

PMID:
24125749
7.

WNT signaling pathway and stem cell signaling network.

Katoh M, Katoh M.

Clin Cancer Res. 2007 Jul 15;13(14):4042-5. Review.

8.

Wnt/beta-catenin signaling in cancer stemness and malignant behavior.

Fodde R, Brabletz T.

Curr Opin Cell Biol. 2007 Apr;19(2):150-8. Epub 2007 Feb 16. Review.

PMID:
17306971
9.

Wnt signaling and cancer development: therapeutic implication.

Paul S, Dey A.

Neoplasma. 2008;55(3):165-76. Review.

PMID:
18348648
10.

[Antagonists of Wnt pathway].

Kinoshita Y, Fukumoto S.

Clin Calcium. 2013 Jun;23(6):817-23. doi: CliCa1306817823. Review. Japanese.

PMID:
23719493
11.

Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.

Song L, Li Y, He B, Gong Y.

Clin Colorectal Cancer. 2015 Sep;14(3):133-45. doi: 10.1016/j.clcc.2015.02.001. Epub 2015 Feb 17. Review.

PMID:
25799881
12.

[Canonical Wnt signaling pathway and cellular responses].

Kikuchi A.

Clin Calcium. 2013 Jun;23(6):799-807. doi: CliCa1306799807. Review. Japanese.

PMID:
23719491
13.

Flavonoids and Wnt/β-catenin signaling: potential role in colorectal cancer therapies.

Amado NG, Predes D, Moreno MM, Carvalho IO, Mendes FA, Abreu JG.

Int J Mol Sci. 2014 Jul 8;15(7):12094-106. doi: 10.3390/ijms150712094. Review.

14.

The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma.

Li C, Shi X, Zhou G, Liu X, Wu S, Zhao J.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1384-91. Review.

PMID:
23747891
15.

FoxM1 and Wnt/β-catenin signaling in glioma stem cells.

Gong A, Huang S.

Cancer Res. 2012 Nov 15;72(22):5658-62. doi: 10.1158/0008-5472.CAN-12-0953. Epub 2012 Nov 8. Review.

16.

Drug discovery approaches to target Wnt signaling in cancer stem cells.

Curtin JC, Lorenzi MV.

Oncotarget. 2010 Nov;1(7):552-66. Review.

17.

Phytochemicals as Innovative Therapeutic Tools against Cancer Stem Cells.

Scarpa ES, Ninfali P.

Int J Mol Sci. 2015 Jul 10;16(7):15727-42. doi: 10.3390/ijms160715727. Review.

18.

The Wnt signaling pathway in cancer.

Duchartre Y, Kim YM, Kahn M.

Crit Rev Oncol Hematol. 2016 Mar;99:141-9. doi: 10.1016/j.critrevonc.2015.12.005. Epub 2015 Dec 24. Review.

PMID:
26775730
19.

Genomic insights into WNT/β-catenin signaling.

Rosenbluh J, Wang X, Hahn WC.

Trends Pharmacol Sci. 2014 Feb;35(2):103-9. doi: 10.1016/j.tips.2013.11.007. Epub 2013 Dec 20. Review.

20.

The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets.

Baarsma HA, Königshoff M, Gosens R.

Pharmacol Ther. 2013 Apr;138(1):66-83. doi: 10.1016/j.pharmthera.2013.01.002. Epub 2013 Jan 14. Review.

PMID:
23328704

Supplemental Content

Support Center